Inclusion of SEL-110 in the treatment regimen with MMA-101 has multiple potential benefits. The first is the potential to reduce or eliminate the formation of proteins in the blood that defend against MMA-101. This opens the possibility of redosing MMA-101 in the future if necessary. Second, SEL-110 may enhance the safety of gene therapy by reducing liver inflammation and ultimately stabilizing liver function. Lastly, SEL-110 may improve MMA-101 efficacy by enhancing expression and durability of the MMUT gene within MMA-101 while reducing immune responses against it. The MMUT gene plays a critical role in making an enzyme that serves as energy-producing centers within the cell.